Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Veru Inc

VERU ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: STRONG BUY

Last Close

$2.73

▲ +1.11%

Market Cap $46.55M · Vol 36.37K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$46.55M

Micro Cap

Div Yield

N/A

Quarterly dividend

EPS Growth

+34.52%

YoY

RSI (14)

75.28

Momentum

Beta

-1.13

vs Market

52W High

$7.32

62.70% below

52W Low

$2.05

33.17% above

Volume

36.37K

Avg 69.41K

P/B

3.04

Price-to-book

ROE

N/A

Return on equity

Free Float

90.79%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Veru Inc (VERU) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does VERU pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+17.17%

+18.18%

+30.62%

+19.21%

YTD

+27.57%

-26.42%

-75.63%

-96.39%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-15,681,260.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-34.75% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.04
P/FCF	N/A
EPS Growth	+34.52%
Outstanding Shares	17.05M

Technical Indicators

50-Day SMA	$2.73
200-Day SMA	$2.50
RSI (14)	75.28
Beta	-1.13
52-Week High	$7.32
52-Week Low	$2.05

Volume Today	36.37K
Avg Daily Volume (30D)	69.41K
Relative Volume	0.52x
Volatility (10D)	85.88
Volatility (30D)	78.57
Free Float	90.79%

Analyst Consensus

STRONG BUY

Current Price $2.73

Mean Target $24.50

52W Low$2.05 52W High$7.32

Current

Target

$2.05 $7.32

Current Analyst target

+797.44% upside potential · 2 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001SCF2T8

ISINUS92536C2026

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateDec 16, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.